DGIdb - DAPSONE Drug Record

DAPSONE chembl:CHEMBL1043 Approved

Alternate Names:

DIAPHENYLSULFONE
DAPSONE
NSC-6091D
ACZONE
DIAMINODIPHENYLSULFONE
J04BA02
NSC-6091
4,4'-SULFONYLBISBENZENAMINE
4-(4-AMINOPHENYLSULFONYL)BENZENAMINE
1,1'-SULFONYLBIS[4-AMINOBENZENE]
P,P-SULPHONYLBISBENZENAMINE
4,4'-SULFONYLDIANILINE
4-(4-AMINOPHENYLSULFONYL)ANILINE
4,4'-DIAMINODIPHENYL SULPHONE
P,P-SULPHONYLBISBENZAMINE
BIS(4-AMINOPHENYL)SULFONE
1,1'-SULFONYLBIS(4-AMINOBENZENE)
4,4'-SULFONYLBISANILINE
4,4'-DIAMINODIPHENYLSULFONE
4-AMINOPHENYL SULFONE
4,4'-SULFONYLBISBENZENEAMINE
BIS(P-AMINOPHENYL) SULFONE
4,4'-DIAMINODIPHENYL SULFONE
4,4'-DAPSONE
DDS
4-(4-AMINO-BENZENESULFONYL)-PHENYLAMINE
4,4'-SULFONYLDIANILIN
P,P'-DIAMINODIPHENYL SULFONE
DADPS
P-AMINOPHENYL SULFONE
chembl:CHEMBL1043
chemidplus:80-08-0
rxcui:3108
drugbank:00250
pubchem.compound:2955

Drug Info:

(2 More Sources)

Publications:

Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.
Cai F et al., 2018, Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01., Intern Med J
Chen WT et al., 2018, The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions., J Invest Dermatol
Tempark T et al., 2017, Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population., Pharmacogenet Genomics
Zhang FR et al., 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome., N Engl J Med
Wang H et al., 2013, Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China., J Invest Dermatol
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Yue Z et al., 2018, Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01., J Invest Dermatol
Luzzatto L et al., 2014, G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications., Br J Haematol
Tungsiripat M et al., 2008, Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic., J Int Assoc Physicians AIDS Care (Chic)
Alloueche A et al., 2004, Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial., Lancet
Sulo J et al., 2002, Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial., Lancet
Youngster I et al., 2010, Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review., Drug Saf
Luzzatto L, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics., Lancet

DAPSONE HLA-B

Interaction Score: 1.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29512326 29458119 28885988 24152261 23604100

Sources:
PharmGKB
DAPSONE GNRH1

Interaction Score: 1.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16123131

Sources:
NCI
DAPSONE HLA-A

Interaction Score: 0.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29233746

Sources:
PharmGKB
DAPSONE CYB5R3

Interaction Score: 0.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAPSONE G6PD

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24372186 18349424 15183620 12387962 20701405 20599264

Sources:
PharmGKB FDA
DAPSONE HLA-DRB1

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29233746

Sources:
PharmGKB
DAPSONE CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
DAPSONE CYP3A4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB
DAPSONE CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
DAPSONE CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

NCI: DDS
- Version: 14-September-2017
Alternate Names:

C415 NCI drug code

Drug Info:

Publications:

Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.
DTC: DAPSONE
- Version: 02-September-2020
Alternate Names:

CHEMBL1043 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: dapsone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Yue Z et al., 2018, Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01., J Invest Dermatol

Sulo J et al., 2002, Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial., Lancet

Luzzatto L, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics., Lancet

TTD: Dapsone
- Version: 2020.06.01
Alternate Names:

D0MA9N TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1043
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Dapsone
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

DAPSONE Drug Record

DAPSONE chembl:CHEMBL1043 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29512326 29458119 28885988 24152261 23604100

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16123131

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29233746

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24372186 18349424 15183620 12387962 20701405 20599264

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29233746

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9187528 22931300

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

NCI: DDS

Alternate Names: C415 NCI drug code

Drug Info:

Publications: Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.

DTC: DAPSONE

Alternate Names: CHEMBL1043 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: dapsone

Alternate Names:

Drug Info:

TTD: Dapsone

Alternate Names: D0MA9N TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1043

Alternate Names:

Drug Info:

Publications:

FDA: Dapsone

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
29512326 29458119 28885988 24152261 23604100

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16123131

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
29233746

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24372186 18349424 15183620 12387962 20701405 20599264

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
29233746

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9187528 22931300

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

C415 NCI drug code

Publications:

Dharap et al., 2005, Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide., Proc. Natl. Acad. Sci. U.S.A.

Alternate Names:

CHEMBL1043 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D0MA9N TTD Drug ID